title: Randomized, controlled trial of telcagepant for the acute treatment of migraine.
abstract: BACKGROUND
  The neuropeptide calcitonin gene-related peptide (CGRP) plays a key role in migraine pathophysiology. In this large phase 3 clinical trial, we sought to confirm the efficacy of telcagepant, the first orally bioavailable CGRP receptor antagonist.
  
  
  METHODS
  Adults with migraine with or without aura (International Headache Society criteria) treated a moderate or severe attack with oral telcagepant 50 mg (n = 177), 150 mg (n = 381), 300 mg (n = 371), or placebo (n = 365) in a randomized, double-blind trial. The 5 co-primary endpoints were pain freedom, pain relief, and absence of photophobia, absence of phonophobia, and absence of nausea, all at 2 hours postdose. The key secondary endpoint was 2-24 hour sustained pain freedom. The prespecified primary efficacy analyses evaluated the 150 mg and 300 mg groups; the 50-mg group was included on an exploratory basis to further characterize the dose response but was not prespecified for analysis. Tolerability was assessed by adverse experience reports.
  
  
  RESULTS
  Telcagepant 300 mg was more effective (p <or= 0.001) than placebo on all primary endpoints and the key secondary endpoint, as was telcagepant 150 mg (p <or= 0.05). Telcagepant 300 mg showed a slight numeric advantage over telcagepant 150 mg on most measures. Telcagepant 50 mg values were numerically intermediate between placebo and telcagepant 150 mg and 300 mg. The percentages of patients with adverse experiences were 32.2% for telcagepant 50 mg, 32.0% for telcagepant 150 mg, 36.2% for telcagepant 300 mg, and 32.2% for placebo.
  
  
  CONCLUSIONS
  This study confirmed previous findings that telcagepant 300 mg was effective at relieving pain and other migraine symptoms at 2 hours and providing sustained pain freedom up to 24 hours. In this study, telcagepant 150 mg was also effective. Telcagepant was generally well tolerated.
authors.affiliation: Merck Research Laboratories, North Wales, PA 19454-1099, USA.
authors.forename: K M
authors.initials: KM
authors.lastname: Connor
authors.forename: R E
authors.initials: RE
authors.lastname: Shapiro
authors.forename: H-C
authors.initials: HC
authors.lastname: Diener
authors.forename: S
authors.initials: S
authors.lastname: Lucas
authors.forename: J
authors.initials: J
authors.lastname: Kost
authors.forename: X
authors.initials: X
authors.lastname: Fan
authors.forename: K
authors.initials: K
authors.lastname: Fei
authors.forename: C
authors.initials: C
authors.lastname: Assaid
authors.forename: C
authors.initials: C
authors.lastname: Lines
authors.forename: Tony W
authors.initials: TW
authors.lastname: Ho
mesh_terms: D000208:Acute Disease; D000328:Adult; D001381:Azepines / Q000008:administration & dosage* / Q000009:adverse effects; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D012001:Hyperacusis / Q000188:drug therapy / Q000209:etiology; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D009325:Nausea / Q000209:etiology; D017063:Outcome Assessment, Health Care; D010147:Pain Measurement; D020795:Photophobia / Q000188:drug therapy / Q000209:etiology; D010919:Placebos; D011788:Quality of Life; D018015:Receptors, Calcitonin Gene-Related Peptide / Q000378:metabolism; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D001381:Azepines; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D007093:Imidazoles; D010919:Placebos; D018015:Receptors, Calcitonin Gene-Related Peptide; C525458:telcagepant; D015740:Calcitonin Gene-Related Peptide